BioMarin makes enzyme-replacement drugs for rare, often fatal genetic diseases—think ultra-niche medicines for conditions most people have never heard of, like MPS IVA or Batten disease. It's a biotech that turns tiny patient populations into billion-dollar fr
Money comes from selling these orphan drugs globally—revenue hit USD 3.22B in 2025 with a 77% gross margin, but net margin is thin at 10.8% due to heavy R&D and commercialization costs. Sales are recurring as patients need lifelong treatment, though quarterly
Rare-disease drugs face little competition because patient populations are tiny and regulatory hurdles are steep—competitors like Sanofi and Ultragenyx would need years and billions to replicate each therapy. But the moat is eroding: Voxzogo's achondroplasia m
Sell (sector percentile 28) — value C+, growth C-, profitability B, momentum B-, revisions C+. Updated daily, sector-relative, identical for every user.
Key events, in time order
Deal adds Ph1/2a asset in rare genetic disease HPP, a market with an approved drug doing ~$2B annualized sales
Q2 sales growth and strong Voxzogo momentum drive guidance raise
Preview suggests lack of beat ingredients; focus on key expectations
Combines genetic medicines with antisense expertise for a condition with no approved therapies
None yet
None yet
BioMarin Pharmaceutical Inc. is acquiring Alesta for $275m, gaining access to a rare genetic disease asset. The deal is driven by the validated market for HPP, with significant sales potential.
Main discussion
Different voices
$BMRN announced a plan to acquire Alesta for $275m upfront, gaining access to a Ph1/2a asset in a rare genetic disease (HPP) HPP is a market validated by one approved drug (Strensiq) which has $2bn in annualized sales; competitor framed $3-5bn market
+Initiations 8/19: $AGMB $AKTS $ALNY $ASND $BCAX $BEKE $BMRN $CAH $CATX $DRIO $HCSG $PRME $ZM . -Initiations 8/19: $AFL $CRCT
$MRNA is up almost 100% today Now its personalized cancer vaccine with Merck has succeeded in a Phase 3 melanoma trial. Genomics is quietly coming back to life Full research and ecosystem map: http://10xdisruptivestocks.substack.com/p/best-genomics-stocks Genomics Ecosystem: • DN
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
